GDOC ETF Holdings

Holdings

Symbol	Grade	Price % Change	Allocation
LLY	F	-4.93	10.82
BSX	B	-0.69	7.10
ISRG	A	-1.89	5.64
ABBV	F	-2.74	5.30
AMGN	D	-4.16	4.58
PODD	A	-0.40	4.46
ABT	B	0.76	3.90
MRK	F	-2.08	3.72
DHR	D	-3.71	3.61
UNH	B	-0.16	3.34
BMRN	F	-3.32	2.78
VEEV	C	-7.12	2.14
ARGX	B	-5.18	2.06
NBIX	D	-4.42	1.79
ALNY	D	-8.67	1.76
IDXX	F	-0.65	1.56
MTD	F	-4.70	1.47
MDGL	C	-4.66	0.77
CGON	D	-7.34	0.76
NTRA	B	-3.34	0.71
PCVX	D	-6.31	0.69
RARE	F	-6.07	0.69
WST	C	-6.99	0.69
ROIV	D	-3.78	0.60
GMAB	F	-2.79	0.60
ALGN	D	0.92	0.57
BPMC	D	-7.28	0.55
XENE	D	-4.60	0.53
TMDX	F	-8.92	0.45
IRTC	C	-3.58	0.41
CLDX	F	-8.51	0.32
ANAB	F	-5.80	0.21

Represented by ETF Holdings

Keywords: S&P 500 Medicine Biopharmaceutical Biotechnology Cancer Life Sciences Diabetes Inflammation Autoimmune Disease Clinical Medicine Glucose Monoclonal Antibody Nasdaq 100 Pharmaceutical Products Acid Amyloid Antibiotics Antibodies Cholesterol Clinical Development

Industries: Biotechnology Medical Devices Diagnostics & Research Drug Manufacturers - Major Medical Instruments & Supplies Health Care Plans Health Information Services Long-Term Care Facilities

Recent News for Goldman Sachs Future Health Care Equity ETF & its Holdings

Date	Stock	Title
Nov 16	ABBV	Why AbbVie’s (ABBV) Drug Setback Creates A Prime Buy-The-Dip Moment
Nov 16	LLY	Lilly's tirzepatide reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesity
Nov 16	LLY	The weight-loss frenzy is making some pharma stocks much more volatile. Will the drama continue?
Nov 16	ABT	Plant-Based API Market Poised To Hit $52 Billion By 2034, Driven By Psychedelics And Cannabinoids
Nov 15	BPMC	Blueprint Medicines' Growth With AYVAKIT And Next-Gen Oncology Drugs
Nov 15	MDGL	Madrigal Pharmaceuticals gains amid takeover speculation
Nov 15	MRK	How analysts are reacting to RFK Jr. as Trump's HHS pick
Nov 15	DHR	Life sciences stocks viewed positively at TD Cowen despite post-election weakness
Nov 15	BSX	Boston Scientific Corporation (BSX) UBS Global Healthcare Conference (Transcript)
Nov 15	ABBV	Pharma Stock Roundup: AZN, BAYRY's Earnings, ABBV's Pipeline Setback
Nov 15	MRK	Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer Therapy
Nov 15	AMGN	Large pharmas, biotechs down as industries grapple with RFK Jr. at HHS
Nov 15	LLY	Large pharmas, biotechs down as industries grapple with RFK Jr. at HHS
Nov 15	ABBV	U.S. Pharma is largely immune from 'MAHA' impact: Wolfe
Nov 15	LLY	U.S. Pharma is largely immune from 'MAHA' impact: Wolfe
Nov 15	ALGN	Medtech shouldn't be greatly impacted by RFK Jr. at HHS, Wells Fargo says
Nov 15	MRK	The Strong Earnings Posted By Merck (NYSE:MRK) Are A Good Indication Of The Strength Of The Business
Nov 15	GMAB	Genmab A/S (GMAB): Among 12 High Growth Large Cap Stocks to Buy Now
Nov 15	MRK	Powell Speaks The Truth - Market Does Not Like It, Consternation About Kennedy, Gaetz, And Hegseth
Nov 15	LLY	Powell Speaks The Truth - Market Does Not Like It, Consternation About Kennedy, Gaetz, And Hegseth

Goldman Sachs Future Health Care Equity ETF is an exchange traded fund launched and managed by Goldman Sachs Asset Management, L.P. The fund invests in the public equity markets across the globe. It invests in stocks of companies operating across health care including genomics, precision medicine, technology-enabled procedures, and digital healthcare sectors. The fund invests in growth and value stocks of companies across diversified market capitalization. The fund employs fundamental analysis and quantitative with to create its portfolio. It seeks to benchmark the performance of its portfolio against the MSCI ACWI Health Care Index. The fund employs proprietary research to create its portfolio. Goldman Sachs Future Health Care Equity ETF was formed on November 9, 2021 and is domiciled in the United States.
Exchange Traded Funds SPDR Synthetic Replication Genomics Goldman Sachs

ETF Components for GDOC - Goldman Sachs Future Health Care Equity ETF